AU2002251140B2 - Chemical derivatives and their use as anti-telomerase agent - Google Patents

Chemical derivatives and their use as anti-telomerase agent Download PDF

Info

Publication number
AU2002251140B2
AU2002251140B2 AU2002251140A AU2002251140A AU2002251140B2 AU 2002251140 B2 AU2002251140 B2 AU 2002251140B2 AU 2002251140 A AU2002251140 A AU 2002251140A AU 2002251140 A AU2002251140 A AU 2002251140A AU 2002251140 B2 AU2002251140 B2 AU 2002251140B2
Authority
AU
Australia
Prior art keywords
radical
alkyl
optionally substituted
amino
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2002251140A
Other languages
English (en)
Other versions
AU2002251140A1 (en
Inventor
Thomas Caulfield
Gilles Doerflinger
Francois Hamy
Abdelazize Laoui
Patrick Mailliet
Jean-Louis Mergny
Jean-Francois Riou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharma SA
Original Assignee
Aventis Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR0103916A external-priority patent/FR2822468B1/fr
Application filed by Aventis Pharma SA filed Critical Aventis Pharma SA
Publication of AU2002251140A1 publication Critical patent/AU2002251140A1/en
Application granted granted Critical
Publication of AU2002251140B2 publication Critical patent/AU2002251140B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2002251140A 2001-03-23 2002-03-22 Chemical derivatives and their use as anti-telomerase agent Ceased AU2002251140B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
FR01/03916 2001-03-23
FR0103916A FR2822468B1 (fr) 2001-03-23 2001-03-23 Derives chimiques et leur application comme agent anti-telomerase
FR01/10370 2001-08-02
FR0110370 2001-08-02
PCT/FR2002/001005 WO2002076975A1 (fr) 2001-03-23 2002-03-22 Derives chimiques et leur application comme agent antitelomerase

Publications (2)

Publication Number Publication Date
AU2002251140A1 AU2002251140A1 (en) 2003-03-27
AU2002251140B2 true AU2002251140B2 (en) 2007-03-15

Family

ID=26212933

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002251140A Ceased AU2002251140B2 (en) 2001-03-23 2002-03-22 Chemical derivatives and their use as anti-telomerase agent

Country Status (11)

Country Link
EP (1) EP1373252A1 (enExample)
JP (1) JP2004524349A (enExample)
AR (1) AR034297A1 (enExample)
AU (1) AU2002251140B2 (enExample)
CA (1) CA2442012A1 (enExample)
CO (1) CO5380035A1 (enExample)
IL (2) IL158056A0 (enExample)
MX (1) MXPA03008269A (enExample)
MY (1) MY130957A (enExample)
PE (1) PE20020959A1 (enExample)
WO (1) WO2002076975A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002314252A1 (en) 2001-05-28 2002-12-09 Aventis Pharma S.A. Chemical derivatives and the use thereof as an anti-telomerase agent
US7173032B2 (en) * 2001-09-21 2007-02-06 Reddy Us Therapeutics, Inc. Methods and compositions of novel triazine compounds
WO2003055866A1 (en) * 2001-12-21 2003-07-10 Bayer Pharmaceuticals Corporation Quinazoline and quinoline derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents
WO2004001018A2 (en) * 2002-06-25 2003-12-31 The Center For Blood Research, Inc. Vacuolins
FR2850970B1 (fr) * 2003-02-07 2006-07-07 Aventis Pharma Sa Derives chimiques se liant de maniere tres specifique aux structures d'adn en g-quadruplexe et leur application comme agent anticancereux specifique
US8309562B2 (en) 2003-07-03 2012-11-13 Myrexis, Inc. Compounds and therapeutical use thereof
CA2531327A1 (en) 2003-07-03 2005-01-13 Myriad Genetics, Inc. Compounds and therapeutical use thereof
CA2592900A1 (en) 2005-01-03 2006-07-13 Myriad Genetics Inc. Nitrogen containing bicyclic compounds and therapeutical use thereof
US8258145B2 (en) 2005-01-03 2012-09-04 Myrexis, Inc. Method of treating brain cancer
JP2008540585A (ja) * 2005-05-19 2008-11-20 プロメティック・バイオサイエンスィズ・インコーポレーテッド 転移性メラノーマ及び他の癌を治療するための化合物、そのような化合物を含有する組成物、および治療方法
JP2009545592A (ja) * 2006-07-31 2009-12-24 プリーシス・ファーマシューティカルズ・インコーポレイテッド コード化小分子ライブラリーからのオーロラキナーゼ阻害剤
US8415340B2 (en) * 2007-07-25 2013-04-09 Bristol-Myers Squibb Company Triazine kinase inhibitors
FR2948686B1 (fr) * 2009-07-30 2011-08-19 Biomerieux Sa Nouveaux substrats de peptidase
US20210024455A1 (en) * 2018-03-20 2021-01-28 Hiroshima University Compound which inhibits telomere-binding protein, and telomere-binding protein inhibitor containing same

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9206768D0 (en) * 1992-03-27 1992-05-13 Jarman Michael New compounds for use in the treatment of cancer
JPH1160573A (ja) * 1997-08-22 1999-03-02 Nippon Kayaku Co Ltd トリアジン誘導体及びテロメラーゼ阻害剤
US6262053B1 (en) * 1999-06-23 2001-07-17 Parker Hughes Institute Melamine derivatives as potent anti-cancer agents
IL149402A0 (en) * 1999-11-29 2002-11-10 Aventis Pharma Sa Arylamine derivatives and their use as anti-telomerase agent
ATE511858T1 (de) * 2002-02-05 2011-06-15 Astellas Pharma Inc 2,4,6-triamino-1,3,5-triazin-derivat

Also Published As

Publication number Publication date
IL158056A0 (en) 2004-03-28
EP1373252A1 (fr) 2004-01-02
CA2442012A1 (fr) 2002-10-03
MY130957A (en) 2007-07-31
IL158056A (en) 2010-02-17
JP2004524349A (ja) 2004-08-12
CO5380035A1 (es) 2004-03-31
MXPA03008269A (es) 2004-10-15
WO2002076975A1 (fr) 2002-10-03
PE20020959A1 (es) 2002-12-17
AR034297A1 (es) 2004-02-18

Similar Documents

Publication Publication Date Title
US20090226411A1 (en) Chemical derivatives and their application as antitelomerase agents
CA2611438C (en) Cyclic anilino-pyridinotriazines
RU2598606C2 (ru) КРИСТАЛЛИЧЕСКАЯ ТОЗИЛАТНАЯ СОЛЬ (8S,9R)-5-ФТОР-8-(4-ФТОРФЕНИЛ)-9-(1-МЕТИЛ-1Н-1,2,4-ТРИАЗОЛ-5-ИЛ)-8-9-ДИГИДРО-2Н-ПИРИДО[4,3,2-de]ФТАЛАЗИН-3(7Н)-ОНА
AU2179001A (en) Arylamine derivatives and their use as anti-telomerase agent
US20100160310A1 (en) 2,4 (4,6) pyrimidine derivatives
US6995175B2 (en) Chemical derivatives and their application as antitelomerase agent
Domagala et al. Quinolone antibacterials containing the new 7-[3-(1-aminoethyl)-1-pyrrolidinyl] side chain: the effects of the 1-aminoethyl moiety and its stereochemical configurations on potency and in vivo efficacy
CZ20021008A3 (cs) Deriváty chinazolinu, způsob jejich přípravy a farmaceutický prostředek, který je obsahuje
JP6257835B2 (ja) 新規なトリアゾロピリミジノン又はトリアゾロピリジノン誘導体、及びこれらの用途
JP2004524349A (ja) 化学的誘導体および抗テロメラーゼ剤としてのその使用
US7179816B2 (en) Chemical derivatives and their application as antitelomerase agents
US6645964B1 (en) Chemical derivatives and their application as antitelomerase agent
MXPA05007648A (es) Derivados quimicos que se unen de manera muy especifica a las estructuras de adn en g - cuadruplex y su aplicacion como agente anticanceroso especifico.
WO2019006322A1 (en) HETEROCROMATINE GENE REPRESSION INHIBITORS
Darwish et al. Potential anticancer agents: Design, synthesis of new pyrido [1, 2-a] benzimidazoles and related derivatives linked to alkylating fragments
AU2017364805B2 (en) Crystal of pyrido[3, 4-d]pyrimidine derivative or solvate thereof
EP3098222B1 (en) Fused acridine derivative and pharmaceutical composition, preparation method and use thereof
AU2002229859B2 (en) Chemical derivatives and their use as anti-telomerase agent
AU2010240717A1 (en) Process for the preparation of 4-(3-chloro-2-fluoro-anilino)-7-methoxy-6-[1- (N-methylcarbamoylmethyl)-piperidin-4-yl]quinazoline

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired